 of daili summari
softwar top research
report read investor
full comment requir non-u analyst conflict disclosur
pleas click link
continu upsid prophi acut potenti rais pt
new emerg robust
updat pt propos gsk agreement acquir tsro
data continu impress among competit
bite develop continu focu shift long half-lif agent
chp surviv data present smash success san diego
preview focu holiday outlook
buyer wari bearish trend pe price settl lower novemb
price prior day market close estimate unless otherwis note
oil strategi made alberta polici
 cloud product price
find research
insight www rbcinsightresearch com global research destin web contact capit market sale
repres access global research site use ipad app research
valu usd unless otherwis note
continu upsid prophi acut potenti rais
pt
even share appreci last two week believ
share continu undervalu likelihood success futur market
opportun lead drug prophylaxi see good
po ph iii result on-demand treatment potenti
market increasingli believ overlook updat
model reflect believ could addit potenti
annual out-year revenu on-demand set back recent
favor data rais price target note
remain favorit small-cap idea
even share appreci last two week believ
share continu undervalu likelihood success futur market
opportun lead drug prophylaxi see good
po ph iii result on-demand treatment potenti
market increasingli believ overlook updat
model reflect believ could addit potenti
annual out-year revenu on-demand set back recent
favor data rais price target note
remain favorit small-cap idea
understand investor primari focu ph iii
prophylaxi readout given larg well-defin opportun see
underappreci valu on-demand set
continu see high probabl success prophylact
set data remain signific potenti upsid driver
coupa deliv beat rais guidanc view fundament
solid organ bill growth low ttm margin
remain posit make modest adjust model pt reiter
headlin bill y/i much higher rbc/ street
even adjust acquisit impact aquiire/ dcr think grew
low rang consist
also impress rate spend manag growth
vs under-scor scale compani
overal make modest chang model continu view coupa
innov player broad spend manag market abl
sustain growth improv leverag
valu usd unless otherwis note
valu usd unless otherwis note
new emerg robust
deliv above-market growth top-line ebitda
greater custom reach cross-sel opportun robust new molecul
robust pipelin also increas cash gener lower capit intens
lead signific sharehold return ev/ebitda
scarciti valu ag pure-play find stock quit attract tweak
estim lithium separ rais target
host first investor day ag pure-play overal see ebitda
increas ag ebitda total
ebitda margin increas also expect
lower sg annual save remaind
due exit dupont tsa consolid legaci back offic
system one sap instanc
new leader crop protect market plan spend
annual sale five year manag highlight three
key competit advantag new post-it combin integr
dupont crop protect organ minim custom overlap
strong local country-level expertis new molecul
impress plan return capit sharehold year
declar regular quarterli dividend prior dividend
plan increas dividend futur year in-line net
incom growth also author initi share repurchas program
execut systemat togeth dividend
buy-back increas result plan return sharehold
maintain outperform overal ag market condit could
deliv top-line growth ebitda growth increas
cash return sharehold tweak estim
lithium separ rais target
updat pt propos gsk agreement acquir tsro
tsro acquisit fit nice gsk ambit compet next-
gener oncolog treatment space expect deal close
addit competit bid see major anti-competit concern emerg
block consumm deal rais price
propos acquisit
expect gsk acquisit tsro close forese major
impedi sale morn tsro announc reach
definit agreement glaxosmithklin gsk acquir
cash repres premium friday close price near
tripl tsro price pre-acquisit interest announc see note
deal valu tsro approxim roughli multipl
valu usd unless otherwis note
valu usd unless otherwis note
valu usd unless otherwis note
peak sale estim larg come wed
heard investor expect potenti acquisit price larg
max expect deal close given see anticompetit
concern given broad parpi io competit see unexpectedli high price
elicit competit bid anticip broad sharehold favor
deal
monday two present stood us de-risk
weekend concern surround venclexta competit risk agio idhmut
portfolio well magnitud benefit confer agio idhmut
inhibitor idhifa tibsovo given idhmut patient may differ response/
surviv dynam vs broader aml popul present uk
 suggest tibsovo idhifa appear confer benefit vs appropri match
idhmut aml patient treat chemotherapi soc
data continu impress among competit
roch poster includ drug-target-drug complex dtdc reaction
switch patient could intensifi switch given longer half-
life roch present data trial
antibodi soliri switch patient poster demonstr efficaci
pnh patient focu patient switch arm
experienc drugtargetdrug complex dtdc mediat reaction
manifest form skin rash though sever immun
event remain somewhat unclear reaction occur post-
switch period day respect resolv day
topic steroid interrupt treatment schedul
sever reaction remain somewhat question anticip
type reaction could intensifi patient switch vs soliri
could becom increas issu competit agent epitop
distinct could help defend market posit
new competit entrant eventu emerg pnh
bite develop continu focu shift long half-lif agent
present data sever bite program notabl bcma
target bite potenti compet off-the-shelf
immunotherapi vs car-t strategi lucr multipl myeloma space
saw new neg surpris safeti
compel evid dose-respons anti-tumor activ rrmm respons
rate improv g/d still mrd neg scr
valu usd unless otherwis note
valu usd unless otherwis note
valu usd unless otherwis note
respond lower dose take total respond
continu infus burdensom like read-
management note dose-escal continu could
efficaci data deeper amgn pipelin impress
r/r aml await data amgn molecul within
class
last week host essent ceo mark casal cfo lawrenc mcale
seri investor meet overal tone meet posit
price price declin year ago level loan qualiti remain
excel signific sign deterior manufactur qualiti
manag believ current busi price produc mid-teen roe
essent likewis posit industri move toward granular
price engin see key risk manag tool time
credit risk transfer much discuss compani recent iln
transact benefit produc capit risk manag loss
mitig ceo mark casal reiter comment made earn call
compani would like structur anoth iln relat
book would look continu use tool regular compon long-
term risk manag view one import point
come meet notabl develop busi model
compani gener essent particular
capit manag manag remain focus opportunist
alloc capit express urgenc implement buy-back
dividend program current underwrit activ gener
chp surviv data present smash success san
last night present detail result trial
adcetri brentuximab vedotin chp vs standard care chop ptcl
patient attend present sgen investor event
came away highli impress os kaplan-mei km curv see
exhibit establish mark separ chp
chop arm biomark data suggest potenti larger expect
market opportun major non-alcl patient
posit commentari nccn t-cell lymphoma chair dr
steven horwitz highli favor suggest likelihood strong nccn
recommend may help uptak amongst commun physician
hl uptak lag
valu cad unless otherwis note
preview focu holiday outlook
hbc report result decemb bmo confer call take place
day et dial-in
hbc report result decemb bmo confer call take place
day et dial-in expect investor focu
primarili outlook top-lin trend holiday sell period
reiter price target sector perform rate valu hbc use
sotp approach appli multipl blend rent-
adjust ebitda retail oper reflect estim valu
investor focu expect investor focu report outlook
sale growth holiday sell period across canada
compstore notabl variat across hbc banner updat
previous announc restructur program save realiz date
potenti commentari real estat strategi
look adj ebitda vs last year consensu
forecast sale yoy lower yoy sale
partial off-set modest gross margin improv bp yoy lower
sg sale bp yoy drive adjust ebitda forecast
expect much volatil around id sale given adjusted/low
top-line guidanc analyst day day left quarter howev
consensu model worst gross margin contract yr think
possibl ep upsid industri profit growth improv sequenti benefit
come continu restock kroger initi reiter outperform
valu usd unless otherwis note
analyst day octob day left quarter
compani updat id sale expect consensu expect
come accordingli expect major surpris id sale
rbce believ small ep beat possibl y/i benefit
ration price environ food retail margin ppi
compani specif initi extract sourc concess
believ gross margin upsid con estim y/i ultim
opportun ep beat rbce vs con
resourc put behind driver long-term growth mani smaller
oper lack believ compani well posit share gain
altern digit profit give us confid target reiter
outperform pt
valu usd unless otherwis note
valu usd unless otherwis note
compar tricki supervalu deal close quarter
entiti report chang howev think pro forma
guidanc come follow svu oper miss unexpect
addit financ cost estim pro-forma ebtida vs guid
ep dilut vs guid posit low doubl digit
report structur compar quarter messi
supervalu deal close day quarter end svu
report segment chang howev two larg oper
miss svu wholesal higher expect financ cost
pressur core wholesal believ
adjust year pro-forma adjust ebitda first year accret rbce
ebitda vs guid rbce dilut ep vs guid
ldd accret think state synergi goal high
ltm svu wholesal ebitda sinc expect first year progress
lack thereof immedi obviou quarter like
enjoy sequenti eas freight pressur benefit despit
organ top-line quarter rbce vs con ahead ep
rbce vs con reiter sector perform pt
expect sale declin japan earn key neg
outlook call though capit return better prior expect
modest earn growth expect slow top-lin growth
view share expens rel peer book ex-aoci
host annual outlook confer call provid guidanc
sale oper margin capit manag plan manag
strateg plan remain consist heard recent held
financi analyst brief septemb includ focu profit
growth includ digit direct initi invest infrastructur
improv effici maintain stabl margin return capit
japan sale guidanc lower expect key neg view
outlook call japan sale growth includ first third sector
product guid low singl digit declin vs prior
expect y/i growth first third sector sale
expect declin similar low singl digit rate quit time
cautiou outlook japan sale growth given lack new
product could propel growth forward place way see
rel good growth within third sector sale larg driven introduct
new cancer product manag comment call suggest
unlik see similar growth rate next year
valu usd unless otherwis note
valu usd unless otherwis note
capit return guidanc potenti better expect help excess
capit drawdown manag guidanc rang share repurchas
better expect prior assumpt
help us excess capit drawdown holdco
liquid expect approach year-end
data year gener increment provid
addit visibl pipelin initi jakafi life cycl extens
strategi also extens discuss compani manag
confer pipelin strateg direct note clinicaltri gov
list post today believ like reflect entri under-the-radar
potenti high-impact oral antagonist clinic share today
like solid coupl reignit anticip across space
believ stock continu underappreci opportun beyond jakafi
jakafi life cycl extens strategi come greater investor focu
gvhd updat increment posit
under-the-radar oral antagonist look enter
clinic today could repres signific long-term opportun
point investor
report strong bill acceler y/i vs y/
better net custom add acv growth coupl
record net dollar retent compani continu invest heavili
opportun expand ngom rais estim maintain outperform
report strong quarter strength across bill revenu
earn cash-flow calcul bill acceler
y/i bill grew sequenti despit manag expect
season declin seen
strength driven sale execut earlier sale hire impact
product launch data upload dynam view
user conference/ brand om also posit surpris
compani rais fy ngoi beat
overal encourag result reiter outperform
valu usd unless otherwis note
valu usd unless otherwis note
attend provid view key updat emerg
confer monday includ next-gener bcma car-t
approach read-through celg data updat
storm/stomp studi
could next-gen safer yescarta emerg next-gener kite anti-
show interest initi clinic data potenti improv
upon neurotox maintain efficaci
battl bcma car-t earli pick winner
keep eye homebrew car-t
consist storm stomp data addit patient underscor selinexor
potenti mm
novemb us light-vehicl came
last year rbce/bloomberg consensu novemb sale
unit y/i ford sale y/i retail
y/i fleet y/i recal gm stop report monthli sale
howev estim sale y/i rbc/consensu estim
y/i bring ytd unit one
month left year keep full-year us demand view
estim remain unchang
market highlight week could provid clearer pictur
commod gain truce trade war china news delay
rais tariff chines good day boost
commod mine equiti monday posit news regard trade
low inventori level metal combat weaker econom data
china see chart week copper exchang inventori
past week comex net long interest decreas slightli prior
week reuter also report premium import copper china sank
low monday indic weaker demand contrari fall
exchang inventori zinc exchang inventori
mine share trade discount forward curv
share trade discount versu discount one
mine share averag last week best perform group
coal follow copper uranium iron ore
nickel diversifi group zinc
eletropaulo call enel distribuicao sao paulo
valu gbp unless otherwis note
valu usd unless otherwis note
valu usd unless otherwis note
valu usd unless otherwis note
intern of daili
guyana increas resourc base rowan rdc rowan relentless
first option exercis oil strategi made alberta polici
implement what aker bp akerbp ol acquisit licenc
total complet petrofac pfc award north sea contract extens
softwar top research report read investor
novemb
need know within note highlight read softwar
note investor novemb
buyer wari bearish trend pe price settl lower novemb
us spot ethylen price remain flat week thanksgiv
cost fell back lower oil price propylen price declin
season slowdown ampl suppli gave buyer price power
us contract pe price settl lower novemb despit produc
effort push contract month lower oil price ampl suppli
chlor-alkali produc report price increas
oxychem announc price increas yet alunort offlin stringent
import regul india continu weigh price market
particip expect price declin decemb
acetyl methanol price lower inland china despit declin
ethylen price mto econom improv back softer methanol price
us methanol price remain flat given season slowdown
coverag list highlight investor day showcas compound-annual-growth-rate target
revenu adj ebitda investor day focus cost
save plan would result bp adj ebit margin improv
come thursday pm estimate call ihsm discuss
polyolefin market
oil strategi made alberta polici implement
valu usd unless otherwis note
sheer size alberta govern mandat output curtail
like return stockpil back season normal level mid-april
trajectori like continu underpin posit wide rang impact
canadian light heavi oil price
volumetr mandat clear govern defin split
crude qualiti curtail barrel major curtail
slant toward heavi barrel market yet precis identifi
degre cut occur heavi light crude slate
eye govern barrel offlin barrel offlin irrespect
natur canadian crude price discount narrow alongsid improv
region fundament backdrop swift action help flatten
wc term structur current state steep contango irrespect
output cut static natur infrastructur constraint leav canadian
price suscept materi volatil episod swift surg
output cut drastic impact canadian price storag level
littl materi implic cush inventori us balanc given
canadian crude nomin us remain high pipelin
continu run full capac simpli put volum move canada
us storag hub cush remain static announc simpli help
drain swamp inventori western canada
cloud product price perform updat
price measur rbc use case calcul flat q/q price
alibaba googl reduct aw lower-pr
vm reduct lower storag price effect
reduct new cheaper vm
product highlight gpu base offer comput memori
optim vm major platform continu trend integr offer
sap alibaba salesforc aw rackspac new
storag option aw googl cloud migrat offer aw
arm aw aw oracl base instanc
continu measur alibaba aw azur googl rackspac
i/o storag bandwidth overal system
perform ad higher-capac ram cpu instanc test
gb ram vm rackspac follow alibaba perform best overal
system cpu test googl aw perform best network/
bandwidth test rackspac perform best i/o storag test
gb ram vm alibaba follow rackspac perform best overal
system perform googl follow rackspac perform best cpu
test googl aw perform best network/bandwidth
bandwidth test alibaba perform best i/o storag test azur
perform averag test
valu usd unless otherwis note
point ep call market close
need understand multipl cross
current expect ca accret coupl strong opex control enabl
guid jan-qtr ahead street model fundament note aapl/
wireless like sourc headwind vs street model modestli oct-qtr
substanti jan-qtr beyond reflect unit share loss impact
enterpris storag given softer data-point hdd compani coupl
slowdown hyperscal nearlin hdd side like soft brcd
could modest off-set ca think see materi
accret vs expect given alreadi announc plan curtail ca
headcount net/net stick op rate target
see multipl tailwind stack dividend uptick
sizabl accret upsid vs expect via ca attract valuat given
capit market busi name use certain branch subsidiari royal bank canada includ dominion secur inc
capit market llc europ limit royal bank canada hong kong branch royal bank canada sydney branch inform contain
report compil capit market sourc believ reliabl represent warranti express impli made royal
canada capit market affili person accuraci complet correct opinion estim contain
report constitut capit market judgement date report subject chang without notic provid good faith without
legal respons noth report constitut legal account tax advic individu tailor invest advic materi prepar gener
circul client prepar without regard individu financi circumst object person receiv invest
servic contain report may suitabl recommend consult independ invest advisor doubt
suitabl invest servic report offer sell solicit offer buy secur past perform guid
futur perform futur return guarante loss origin capit may occur capit market research analyst compens base
part overal profit capit market includ profit attribut invest bank revenu everi provinc canada state
 countri throughout world law regul type secur invest product may offer
resid well process result secur discuss report may elig sale jurisdict
capit market may restrict publish research report time time due regulatori restrict and/ intern complianc polici
case latest publish research report avail client may reflect recent materi chang applic industri and/or applic subject
compani capit market research report current date set forth research report report circumst
constru solicit act secur broker dealer jurisdict person compani legal permit carri
busi secur broker dealer jurisdict full extent permit law neither capit market affili
person accept liabil whatsoev direct consequenti loss aris use report inform contain herein matter
contain document may reproduc copi mean without prior consent capit market
addit inform avail request
public approv capit market llc member finra nyse sipc regist broker-deal accept
respons report dissemin unit state recipi report regist broker-deal bank act
broker dealer capac wish inform regard effect transact secur discuss report
contact place order capit market llc
public approv dominion secur inc member iiroc canadian recipi report design institut
ontario accredit investor british columbia alberta sophist purchas quebec similar permit purchas provinc
wish inform regard effect transact secur discuss report contact place order
dominion secur inc without way limit forego accept respons report dissemin canada
public approv europ limit el author prudenti regul author regul
conduct author fca prudenti regul author connect distribut unit kingdom materi gener
distribut unit kingdom retail client defin rule fca rbcel accept respons report dissemin
unit kingdom
materi distribut germani europ limit frankfurt branch regul bundesanstalt fr finanzdienstleistungsaufsicht bafin
receiv advic australia
materi distribut australia royal bank canada sydney branch abn afsl materi prepar
gener circul take account object financi situat need recipi accordingli recipi act
materi consid appropri materi regard object financi situat need materi relat acquisit
possibl acquisit particular financi product recipi australia obtain relev disclosur document prepar respect product
